TIAA CREF Investment Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

TIAA CREF Investment Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$1.35M	Buy	112,204 +5,300	+5%	+$78.1K	﹤0.01%	2181
2018 Q4	$1.34M	Sell	106,904 -28,695	-21%	-$396K	﹤0.01%	2165
2018 Q3	$2.01M	Sell	135,599 -41,500	-23%	-$653K	﹤0.01%	2117
2018 Q2	$2.98M	Buy	177,099 +35,787	+25%	+$695K	﹤0.01%	1958
2018 Q1	$3.24M	Sell	141,312 -32,145	-19%	-$715K	﹤0.01%	1836
2017 Q4	$4.49M	Buy	173,457 +62,343	+56%	+$1.26M	﹤0.01%	1673
2017 Q3	$1.64M	Sell	111,114 -18,705	-14%	-$271K	﹤0.01%	2277
2017 Q2	$1.81M	Buy	129,819 +4,636	+4%	+$68.3K	﹤0.01%	2236
2017 Q1	$2.14M	Buy	125,183 +19,078	+18%	+$229K	﹤0.01%	2106
2016 Q4	$1.09M	Buy	106,105 +1,558	+1%	+$14.2K	﹤0.01%	2486
2016 Q3	$1.06K	Sell	104,547 -1,859	-2%	-$20.3K	﹤0.01%	2512
2016 Q2	$1.2M	Buy	106,406 +1,390	+1%	+$17.7K	﹤0.01%	2418
2016 Q1	$1.44M	Buy	105,016 +1,846	+2%	+$26.6K	﹤0.01%	2269
2015 Q4	$1.96M	Buy	103,170 +21,900	+27%	+$476K	﹤0.01%	2170
2015 Q3	$1.52M	Buy	81,270 +65,177	+405%	+$1.11M	﹤0.01%	2309
2015 Q2	$240K	Buy	+16,093	New	+$245K	﹤0.01%	3100
2014 Q4	–	Sell	-3,196	Closed	-$40K	–	3156
2014 Q3	$40K	Sell	3,196 -30,500	-91%	-$296K	﹤0.01%	3118
2014 Q2	$340K	Buy	33,696 +8,332	+33%	+$80.5K	﹤0.01%	3059
2014 Q1	$341K	Buy	+25,364	New	+$358K	﹤0.01%	3029

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TIAA CREF Investment Management's CNCE Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Concert Pharmaceuticals, Inc. (CNCE) stake by 5% in Q1 2019, buying an estimated $78.1K and bringing the position to 112,204 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2181.

TIAA CREF Investment Management first reported a position in CNCE in Q1 2014 and has held it in 19 quarters since. The position peaked at $4.49M in Q4 2017. 92 funds tracked by Wall St. Rank hold CNCE as of Q1 2019.

TIAA CREF Investment Management held 112,204 shares of Concert Pharmaceuticals, Inc. worth $1.35M as of Q1 2019.
TIAA CREF Investment Management bought 5,300 Concert Pharmaceuticals, Inc. shares in Q1 2019, an estimated $78.1K.
Concert Pharmaceuticals, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2181 holding.
TIAA CREF Investment Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and has held it in 19 quarters since.
TIAA CREF Investment Management's Concert Pharmaceuticals, Inc. position peaked at $4.49M in Q4 2017.
92 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.